Apollon Wealth Management’s ImmunityBio IBRX Stock Holding History

Apollon Wealth Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-13,600	Closed	-$24.8K	–	965
2023 Q1	$24.8K	Buy	+13,600	New	+$42.3K	﹤0.01%	856

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

National Bank of Canada Montreal, Quebec, Canada $112B AUM 31.26% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

Apollon Wealth Management's IBRX Position: Q2 2023 in Review

Apollon Wealth Management sold out of ImmunityBio (IBRX) in Q2 2023, closing a stake of 13,600 shares — an estimated $24.8K sold.

Apollon Wealth Management first reported a position in IBRX in Q1 2023 and held it in 1 quarter. The position peaked at $24.8K in Q1 2023. 117 funds tracked by Wall St. Rank hold IBRX as of Q2 2023.

Apollon Wealth Management reported no remaining ImmunityBio position as of Q2 2023 after selling out during the quarter.
Apollon Wealth Management sold 13,600 ImmunityBio shares in Q2 2023, an estimated $24.8K.
Apollon Wealth Management first reported a position in ImmunityBio in Q1 2023 and held it in 1 quarter.
Apollon Wealth Management's ImmunityBio position peaked at $24.8K in Q1 2023.
117 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2023.

Based on Apollon Wealth Management's 13F filing for Q2 2023, filed 4 Aug 2023.